Inrobics

Social AI for wellbeing and personalized rehabilitation

1/1 Photos

Key project data

Target amount

0.75M EUR

Valuations

3.5M EUR

Would AI invest?

74/100

100

Invest Now

AI-Generated Overview

This overview is generated using artificial intelligence based on information available on the platform’s project page and publicly accessible data. It is provided for informational purposes only and does not constitute investment advice, financial guidance, risk assessment, or project scoring. Platforms and project owners are not involved in the creation, review, or endorsement of this content.

AI project overview

Condensed summary based on project data

<h1><span style="font-size:15pt"><span style="font-family:Calibri,sans-serif">Inrobics Social Robotics — Crowdfunding Investor Memo</span></span></h1>
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif">Inrobics builds Alma®, an AI system that runs on small robots, tablets and on-screen characters to guide people through physical and mental exercises — used with children in rehabilitation, patients recovering movement, and older adults in care.</span></span></p>
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong>Sector: </strong>Digital health / assistive-AI &amp; social robotics<strong>   ·   Stage: </strong>Seed / pre-Series A<strong>   ·   HQ: </strong>Leganés (Madrid), Spain<strong>   ·   Raise: </strong>€100K–€350K (platform disclosure)</span></span></p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:none; border-style:none; border-width:medium">
<tbody>
<tr>
<td style="background-color:#eaf0f6; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:613px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">ℹ️ Information, not investment advice. </span></strong><span style="color:black">Capital at risk — you could lose the full amount invested. Full notes are at the end of this memo.</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<h2><span style="font-size:12.5pt"><span style="font-family:Calibri,sans-serif">Snapshot</span></span></h2>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:none; border-style:none; border-width:medium">
<tbody>
<tr>
<td style="background-color:#e7ecf2; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:193px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">1 · Is the price fair? 💶</span></strong></span></span></p>
</td>
<td style="background-color:#fcebeb; border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:420px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">2 / 5</span></strong><span style="color:black"> — The €3.5M pre-money price is about 13 times last year's revenue (€261K). Health-AI companies with proven data and workflow integration change hands at roughly 4x–8x revenue (Nelson Advisors; Windsor Drake, 2026), so this entry price sits above the benchmarks we could find.</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#e7ecf2; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:193px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">2 · Can they reach an exit stage? ⭐</span></strong></span></span></p>
</td>
<td style="background-color:#fbf1d9; border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:420px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">AI SCORE 74 / 100 — Good. </span></strong><span style="color:black">Strongest evidence: a publicly verified founding team of three PhDs and a CE-marked medical product already used in 20 centres by 1,000+ people. Biggest gap: revenue fell from €414K (2024) to €261K (2025), and the €13.1M pipeline is not backed by signed contracts in the pack.</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#e7ecf2; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:193px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">3 · If they do, what could it pay? 🎯</span></strong></span></span></p>
</td>
<td style="background-color:#f0f4f8; border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:420px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">Target ~10x over 5–7 years</span></strong><span style="color:black"> (the standard expectation for seed stage — the company sets no investor target). If a successful sale is reached, illustratively roughly 10x–20x before fees and future dilution. Method: typical health-tech sale multiples of 4x–8x revenue (Nelson Advisors; Windsor Drake, 2026) applied to a modest successful scale, measured against the €3.5M entry price. No comparable exits for this niche were found on record.</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong>How to read the score</strong></span></span></p>
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif">Three answers, one honest note. The fairness score says whether the entry price is supported by the sector benchmarks we could find. The AI Score is our read on whether the company has the building blocks in place to reach a point where a sale or other exit can happen — it rates readiness on the evidence shown, not the chance of success, and even companies with every building block in place fail more often than they succeed, which is why crowdfunding only works as a small part of a spread-out portfolio. The returns range is an illustration of what a successful sale could pay, built from named sector benchmarks — not a forecast. Where something was not in the pack, it did not lower any score — it appears in the questions list instead, so you can ask the company directly before investing. The listing was reviewed by a licensed crowdfunding platform (Startupxplore) before going live. Nothing here is a recommendation.</span></span></p>
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong>What the score bands mean</strong></span></span></p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:none; border-style:none; border-width:medium">
<tbody>
<tr>
<td style="background-color:#d9ebc2; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:153px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">85–100 · Excellent</span></strong></span></span></p>
</td>
<td style="background-color:#d9ebc2; border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:460px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><span style="color:black">All key building blocks for reaching an exit stage are evidenced and strong — rare at this stage</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#faeeda; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:153px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">70–84 · Good</span></strong></span></span></p>
</td>
<td style="background-color:#faeeda; border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:460px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><span style="color:black">Building blocks largely in place, with specific gaps — named in the questions section</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:153px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">50–69 · Average</span></strong></span></span></p>
</td>
<td style="background-color:#faece8; border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:460px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><span style="color:black">Meaningful building blocks missing or weakly evidenced</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#fcebeb; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:153px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">30–49 · Weak</span></strong></span></span></p>
</td>
<td style="background-color:#fcebeb; border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:460px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><span style="color:black">Several core building blocks absent, or the evidence points against them</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#fcebeb; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:153px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">1–29 · Critical</span></strong></span></span></p>
</td>
<td style="background-color:#fcebeb; border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:460px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><span style="color:black">Fundamental building blocks are not visible in the evidence</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p> </p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:none; border-style:none; border-width:medium">
<tbody>
<tr>
<td style="background-color:#eaf0f6; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:613px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">What we could check. </span></strong><span style="color:black">We verified the founders' identities and credentials, the UC3M spin-off origin, the lead investor (Grow Venture Partners), prior grants and awards, and the CE-marked medical-software status against public sources. The revenue, margin, pipeline, MRR and cap-table figures rest on the company's own materials — see the questions section.</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<h2><span style="font-size:12.5pt"><span style="font-family:Calibri,sans-serif">At a glance</span></span></h2>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:none; border-style:none; border-width:medium">
<tbody>
<tr>
<td style="background-color:#edf3e6; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:307px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">✅ Three reasons to look closer</span></strong></span></span></p>
</td>
<td style="background-color:#fbe9e7; border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:307px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">⚠️ Three reasons for caution</span></strong></span></span></p>
</td>
</tr>
<tr>
<td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:307px">
<ul>
<li><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif">A CE-marked medical product already deployed across 20 health and education centres, supporting 1,000+ users, with €500K+ revenue to date (company; consistent with filed accounts).</span></span></li>
<li><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif">A publicly verified founding team of three computer-science PhDs from UC3M, with research stays at USC and Carnegie Mellon, backed again by lead investor Grow Venture Partners (€250K).</span></span></li>
<li><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif">10+ years of R&amp;D behind the product, a national research award (SCIE–Fundación BBVA, 2025), and clinical studies underway with Cruz Roja and McGill (company).</span></span></li>
</ul>
</td>
<td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:307px">
<ul>
<li><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif">Revenue fell from €413,908 (2024) to €261,423 (2025), and 2024 revenue was about 88% dependent on a single client that is also a related party (CUSTER Investigaciones AIE) — per the company's own accounts.</span></span></li>
<li><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif">The €13.1M pipeline and €800K+ of “contracted” 2026 revenue are not backed by signed contracts in the pack, while the plan jumps to €1.0M revenue in 2026.</span></span></li>
<li><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif">The round size and the ownership share you receive are stated three different ways across the company's own documents (see the questions section), and the entry price sits above the sector benchmarks we found.</span></span></li>
</ul>
</td>
</tr>
</tbody>
</table>
<p> </p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:none; border-style:none; border-width:medium">
<tbody>
<tr>
<td style="background-color:#edf3e6; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:613px">
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">Deal terms. </span></strong><span style="color:black">No terms were identified in the reviewed documents that would prevent a crowdfund investor from sharing in the upside. On a sale, money contributed as share capital and premium is returned first, and the rest is split among all shareholders in proportion to their holdings. Full mechanics — including one feature worth checking (a €1 early-exit buy-back) — are at the end of this memo.</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<h2><span style="font-size:12.5pt"><span style="font-family:Calibri,sans-serif">🏢 What the company does</span></span></h2>
<p><span style="font-size:10pt"><span style="font-family:Calibri,sans-serif">Inrobics Social Robotics is a spin-off of the Universidad Carlos III de Madrid (UC3M) that develops Alma®, an artificial-intelligence platform for physical, cognitive and emotional well-being. The company reports that Alma runs across different devices — humanoid robots, tablets and on-screen avatars — rather than depending on any single piece of hardware, guiding users through exercises and generating progress data for professionals. Its customers are clinics, hospitals, rehabilitation and early-intervention centres, schools and nursing homes (sold business-to-business and to the public sector), plus home users reached through care providers. It earns money mainly from software subscriptions and analytics, sometimes bundled with hardware, and reports €500K+ of revenue to date across 20 centres and 1,000+ users. The company operates primarily in Spain, with pilots and distributors in several other countries. This…</span></span></p>

See full overview

Ask question

Ask AI about this project

Beta